Reference market
Open- Regular hours
- 09:30 AM – 04:00 PM EST
- Next holiday
- Nov 26, 2026 · Thanksgiving Day
Equity
Eli Lilly and Company (LLY) perpetual futures
LLY perpetual futures on 20 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade LLYUSDT.
Eli Lilly and Company develops and commercializes human medicines in diabetes, oncology, immunology, neurology, and other therapeutic areas, including collaborations with partners.
$1,440-0.7%NYSE open
Price chart
Interactive TradingView chart
TradingView symbol NYSE:LLY
Loads TradingView's third-party widget (about 1 MB) on demand.
Auto: underlying reference priceOpen in TradingView
Trading data
Perpetual market activity
20/20 live markets
Trading data
Perpetual market activity
Venues
20
Live markets
20/20
24h volume
$11.7MCoverage: 16/20 marketsExchange-reported volume: $39.4M
Open interest
$22.7MCoverage: 17/20 markets
Best liquidity
$2M
Bitget
Tightest spread
+0.1 bps
Bitunix
Highest volume
$4M
Binance
Settlement mix
USDT · 17/20
Perp/spot vol.
0.02x
Spot volume $644.2M
OI / float
0.00%
Float $1.2T
Spot performance
1D+0.85%
5D+6.46%
1M+23.24%
6M+41.54%
YTD+33.77%
1Y+40.55%
Venue matrix
20 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Binance | Trade | LLY/USDT | Trading | $1,440 | 0.0% APR 0.000% every 8h | +3.2 bps | - | $4M | $3.1M | USDT | - | |
 Hyperliquid HIP-3 | Trade | xyz:LLY | Trading | $1,439 | +5.5% APR +0.00063% every 1h | +3.5 bps | - | $2M | $5.7M | USDC | 10x | |
 Gate.io | Trade | LLY/USDT | Trading | $1,440 | 0.0% APR 0.000% every 8h | +21.8 bps | $31K | $720.7K | $405K | USDT | 25x | |
 KuCoin | Trade | LLY/USDT | Trading | $1,439 | 0.0% APR 0.000% every 8h | +9.1 bps | $5.2K | $668.1K | $402.8K | USDT | 20x | |
 OKX | Trade | LLY/USDT | Trading | $1,441 | 0.0% APR 0.000% every 8h | +3.5 bps | $26.5K | $479.6K | $742.4K | USDT | 20x | |
 MEXC | Trade | LLY/USDT | Trading | $1,441 | 0.0% APR 0.000% every 8h | +2.6 bps | $262.4K | $362.1K | $9.5M | USDT | 100x | |
 Bitget | Trade | LLY/USDT | Trading | $1,440 | 0.0% APR 0.000% every 8h | +4.4 bps | $2M | $360.5K | $1.2M | USDT | 20x | |
 Bitunix | Trade | LLY/USDT | Trading | $1,440 | -0.8% APR -0.00076% every 8h | +0.1 bps | $457.1K | $209.6K | $45.2K | USDT | 50x | |
 Bybit | Trade | LLY/USDT | Trading | $1,440 | 0.0% APR 0.000% every 8h | +8.6 bps | $31.7K | $149.7K | $1.2M | USDT | 25x | |
 GRVT | Trade | LLY/USDT | Trading | $1,441 | 0.0% APR 0.000% every 8h | +5.3 bps | $28.2K | $113.3K | $446.8 | USDT | - | |
 BloFin | Trade | LLY/USDT | Trading | $1,441 | -1.7% APR -0.00155% every 8h | +1.0 bps | - | $99.9K | $81.7K | USDT | 20x | |
 HTX | Trade | LLY/USDT | Trading | $1,441 | 0.0% APR 0.000% every 8h | +59.2 bps | $49.6K | $60K | $5.9K | USDT | - | |
 Aster | Trade | LLYUSDT | Trading | $1,440 | 0.0% APR 0.000% every 8h | +10.4 bps | $26.3K | $13.4K | $7K | USDT | - | |
 Crypto.com Exchange | Trade | LLY/USD | Trading | $1,440 | -102.6% APR -0.012% every 1h | +12.7 bps | $10.7K | $1.9K | $39.9K | USD | 50x | |
 Vest | Trade | LLY/USDC | Trading | $1,439 | +5.0% APR +0.00057% every 1h | +9.7 bps | - | - | - | USDC | 25x | |
 BingX | Trade | LLY-USDT | Trading | $1,442 | -5.5% APR -0.00500% every 8h | +3.5 bps | $2M | $1.7M | - | USDT | - | |
 XT.com | Trade | LLY/USDT | Trading | $1,441 | 0.0% APR 0.000% every 8h | +2.9 bps | - | $753.3K | - | USDT | 20x | |
 Deepcoin | Trade | LLY/USDT | Trading | $1,441 | - | +1.3 bps | - | $24M⚠ | $430.8 | USDT | 25x | |
 Ourbit | Trade | LLY/USDT | Trading | $1,440 | 0.0% APR 0.000% every 8h | +2.1 bps | $567.4K | $3M⚠ | $170.1K | USDT | 100x | |
 LBank | Trade | LLY/USDT | Trading | $1,441 | 0.0% APR 0.000% every 8h | +3.1 bps | $694.3K | $701.7K⚠ | $37.5K | USDT | 50x |
Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.
Tokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| LLYonOndo GM | $1,439 | -0.10% | $2.1M | $9.0M | Ethereum · BNB Smart Chain (BEP20) · Solana |
| LLYBbStocks | $1,436 | -0.33% | $1.3M | $920k | BNB Smart Chain (BEP20) |
| LLYXxStocks | $1,428 | -0.85% | $227k | $1.3M | Solana · Arbitrum · BNB Smart Chain (BEP20) · Ink |
| LLYRobinhood | $1,430 | -0.82% | $2k | $777k | Robinhood Chain |
| rLLYTokenized | $1,432 | -0.60% | $137 | $31k | Arbitrum |
| WLLYXxStocks | $1,439 | -0.12% | – | $2k | X Layer · Arbitrum |
| Exchange | Pair | Price | 24h Vol. | Liquidity |
|---|---|---|---|---|
| gateioCEX | LLYON/USDT ↗ | $1,437 | $73k | – |
 uniswapDEX · robinhood | LLY/WETH ↗ | – | – | – |
| uniswapDEX · robinhood | LLY/USDG ↗ | $1,430 | $2k | $103k |
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kBroad liquidity · 12 of 20 venues absorb $10k · Typical cost: +8.4 bps – +20.8 bps
Too thin: Crypto.com Exchange, KuCoin
No fresh book data: HTX, Deepcoin, Binance, Hyperliquid HIP-3, BloFin, Vest
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
LLYTightest spread
LLYHighest volume
LLYFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
Earnings
2027-02-03
Revenue est. $24.6B · Updated 5m ago
Dividend
$1.73
2026-11-13
No unusual perp activity right now.
Reference data
Market context
Reference data
Market context
New York Stock Exchange
Extended-hours reference
Bid1,429.02
Ask1,437.48
Volume455,483
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6DateEPS estimateRevenue estimateGrowthAnalysts
FY 202635.37$91.3B+40%15
FY 202750.45$107B+17%16
FY 202857.77$119.3B+11%10
FY 202966.35$130.7B+10%4
FY 203073.21$141.4B+8%4
Q3 20265.68$22.6B+28%11
Source: FMP · Consensus
Company events
62027-02-03EarningsActual - / Estimate 11.19-
2026-11-13Dividend$1.73-
2026-10-29Earnings · Before market openActual 7.48 / Estimate 5.71Beat
2026-08-14Dividend$1.73-
2026-08-05EarningsActual 8.38 / Estimate 6.40Beat
2026-05-15Dividend$1.73-
Peer comparison
Similar listed perpsRevenue mix
Latest annualUNITED STATESGeographic$43.5B
EuropeGeographic$11.6B
Non USGeographic$6.1B
Analysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $1,445 |
| 12-month target range (low – high) | $940 – $1,650 |
| Ratings in the provider's consensus | 46 |
Price targets as of 2026-11-12
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 6 | 20 | 3 | 1 | 1 |
| Oct 2026 | 6 | 20 | 3 | 1 | 1 |
| Sep 2026 | 6 | 19 | 4 | 1 | 1 |
| Aug 2026 | 6 | 18 | 4 | 1 | 1 |
| Jul 2026 | 6 | 17 | 5 | 1 | 1 |
| Jun 2026 | 6 | 18 | 5 | 1 | 1 |
| May 2026 | 6 | 18 | 6 | 1 | 1 |
| Apr 2026 | 6 | 18 | 6 | 1 | 0 |
| Mar 2026 | 6 | 18 | 6 | 1 | 1 |
| Feb 2026 | 6 | 18 | 7 | 0 | 1 |
| Jan 2026 | 4 | 18 | 8 | 0 | 1 |
| Dec 2025 | 4 | 18 | 8 | 0 | 1 |
Ownership
Institutional · 2026-Q3Free float90.1%847.9M shares
Shares outstanding940.7M shares
Institutional51.3%3,806 investors
Investor count change-1,011
Reference market activity
LLY-PERPDay range (Nov 13)$1.42K$1.44K
52 week$850.51$1.46K
Spot volume447.2K
Average volume-
Price performance
111D+0.8%
5D+6.5%
1M+23.2%
3M+18.9%
6M+41.5%
YTD+33.8%
1Y+40.6%
3Y+134.6%
5Y+456.3%
10Y+1,766.6%
MAX+51,061.7%
Insider activity
FY2026 Q4Acquisitions9 transactions12,225 shares
Dispositions14 transactions46,895 shares
Purchases0Ratio 0.64
Sales1
Insider transactions
25DateReporting persontransactionssharesPriceFilings
Eli Lilly officer Jonsson Patrik reported gifting 704 common shares on Nov 10, 2026 (Form 4, code G), leaving 53,443 shares owned.
Eli Lilly CEO David A. Ricks reported gifting 23,538 common shares on 2026-11-03, leaving him with 555,278 shares owned directly after the transaction.
Eli Lilly officer Daniel Skovronsky reported a gift (G) of 119 Common Stock shares at $0.00, leaving 159,953 shares owned after the transaction.
Eli Lilly officer Hakim Anat (EVP, GC & Secretary) reported an open-market sale of 5,000 common shares at $1,402.52 on 2026-11-02, leaving 4,137 shares owned.
Eli Lilly CFO Lucas Montarce exercised 1,610 restricted stock units into 1,610 common shares, then 678 shares were withheld for taxes at $1,417.54. He holds 17,191 shares after.
Eli Lilly officer Hernandez Edgardo converted 2,530 restricted stock units into 2,530 common shares and had 1,123 shares withheld for taxes at $1,417.54, leaving 47,490 shares owned.
Eli Lilly officer Eric Dozier exercised 2,300 restricted stock units into 2,300 common shares at $0.00, then had 1,019 shares withheld for taxes at $1,417.54. He held 15,520 shares afterward.
Eli Lilly officer Custer Kenneth L. converted 3,220 restricted stock units into 3,220 common shares (M-Exempt) on 2026-11-01, and 1,425 common shares were withheld for taxes (F-InKind) at $1,417.54, leaving 11,935 shares owned.
Eli Lilly officer Adrienne S. Brown exercised 2,530 restricted stock units into 2,530 common shares, then had 1,099 shares withheld for taxes at $1,417.54 under code F. She retained 9,894 shares.
Director Gabrielle Sulzberger was awarded 4 shares of Eli Lilly common stock on 2026-10-19, bringing her holdings to 3,016 shares.
Director Juan R Luciano was awarded 13 shares of Eli Lilly common stock at $1,240.34 each on Oct 19, 2026, a grant rather than an open-market purchase. He held 16,970 shares afterward.
Director Fyrwald J Erik received an award of 8 common shares of Eli Lilly at $1,240.34 per share on 2026-10-19, bringing his holdings to 75,544 shares. This was a grant, not an open-market purchase.
Eli Lilly director Ralph Alvarez received an award of 10 common shares at $1,240.34 per share, a grant rather than an open-market purchase, and held 55,848 shares afterward.
Eli Lilly director Sulzberger Gabrielle was granted 4 shares of Common Stock at $1,164.89 each, an award (not an open-market purchase), bringing her direct holdings to 3,012 shares.
Director Juan R. Luciano received a grant of 14 shares of Eli Lilly common stock at $1,164.89 per share on Sept 21, 2026, an award (not a purchase), leaving 16,957 shares owned.
Filings
76 · Latest SEC filings2026-11-104Insider transaction report (Form 4)
Eli Lilly officer Jonsson Patrik reported gifting 704 common shares on Nov 10, 2026 (Form 4, code G), leaving 53,443 shares owned.
2026-11-044Insider transaction report (Form 4)
Eli Lilly CEO David A. Ricks reported gifting 23,538 common shares on 2026-11-03, leaving him with 555,278 shares owned directly after the transaction.
2026-11-034Insider transaction report (Form 4)
Eli Lilly officer Eric Dozier exercised 2,300 restricted stock units into 2,300 common shares at $0.00, then had 1,019 shares withheld for taxes at $1,417.54. He held 15,520 shares afterward.
2026-11-034Insider transaction report (Form 4)
Eli Lilly officer Adrienne S. Brown exercised 2,530 restricted stock units into 2,530 common shares, then had 1,099 shares withheld for taxes at $1,417.54 under code F. She retained 9,894 shares.
2026-11-034Insider transaction report (Form 4)
Eli Lilly CFO Lucas Montarce exercised 1,610 restricted stock units into 1,610 common shares, then 678 shares were withheld for taxes at $1,417.54. He holds 17,191 shares after.
2026-11-034Insider transaction report (Form 4)
Eli Lilly officer Daniel Skovronsky reported a gift (G) of 119 Common Stock shares at $0.00, leaving 159,953 shares owned after the transaction.
2026-11-034Insider transaction report (Form 4)
Eli Lilly officer Custer Kenneth L. converted 3,220 restricted stock units into 3,220 common shares (M-Exempt) on 2026-11-01, and 1,425 common shares were withheld for taxes (F-InKind) at $1,417.54, leaving 11,935 shares owned.
2026-11-034Insider transaction report (Form 4)
Eli Lilly officer Hakim Anat (EVP, GC & Secretary) reported an open-market sale of 5,000 common shares at $1,402.52 on 2026-11-02, leaving 4,137 shares owned.
2026-11-034Insider transaction report (Form 4)
Eli Lilly officer Hernandez Edgardo converted 2,530 restricted stock units into 2,530 common shares and had 1,123 shares withheld for taxes at $1,417.54, leaving 47,490 shares owned.
2026-10-204Insider transaction report (Form 4)
Director Juan R Luciano was awarded 13 shares of Eli Lilly common stock at $1,240.34 each on Oct 19, 2026, a grant rather than an open-market purchase. He held 16,970 shares afterward.
2026-10-204Insider transaction report (Form 4)
Director Gabrielle Sulzberger was awarded 4 shares of Eli Lilly common stock on 2026-10-19, bringing her holdings to 3,016 shares.
2026-10-204Insider transaction report (Form 4)
Director Fyrwald J Erik received an award of 8 common shares of Eli Lilly at $1,240.34 per share on 2026-10-19, bringing his holdings to 75,544 shares. This was a grant, not an open-market purchase.
2026-10-204Insider transaction report (Form 4)
Eli Lilly director Ralph Alvarez received an award of 10 common shares at $1,240.34 per share, a grant rather than an open-market purchase, and held 55,848 shares afterward.
2026-09-224Insider transaction report (Form 4)
Eli Lilly director Sulzberger Gabrielle was granted 4 shares of Common Stock at $1,164.89 each, an award (not an open-market purchase), bringing her direct holdings to 3,012 shares.
2026-09-224Insider transaction report (Form 4)
Eli Lilly director Ralph Alvarez received an award of 11 common shares at $1,164.89 per share on 2026-09-21 (an Award, not an open-market purchase), leaving 55,838 shares owned after.
2026-09-224Insider transaction report (Form 4)
Eli Lilly director Fyrwald J Erik received an award of 9 shares of Common Stock at $1,164.89 per share, bringing his holdings to 75,536 shares.
2026-09-224Insider transaction report (Form 4)
Director Juan R. Luciano received a grant of 14 shares of Eli Lilly common stock at $1,164.89 per share on Sept 21, 2026, an award (not a purchase), leaving 16,957 shares owned.
2026-09-114Insider transaction report (Form 4)
Eli Lilly officer Seymour Melissa reported disposing of 29 common shares across 2 gift transactions (G-Gift) at $0.00, leaving 1,038 shares owned.
2026-09-043/AInitial insider ownership statement (Form 3)
Adrienne S. Brown filed a Form 3/A with no reportable transactions in common stock, retaining 7,045 shares.
2026-09-044Insider transaction report (Form 4)
On Sep 2, 2026, officer Edgardo Hernandez gifted 13 shares of Eli Lilly common stock at no value, leaving 46,083 shares owned.
2026-09-044Insider transaction report (Form 4)
Officer Dozier Eric gifted 216 shares of Eli Lilly common stock on September 2, 2026.
2026-08-184Insider transaction report (Form 4)
Director Gabrielle Sulzberger received a stock award of 4 common shares of Eli Lilly at $1,183.16 each, holding 3,004 shares after.
2026-08-184Insider transaction report (Form 4)
Director Alvarez Ralph received an award of 10 shares of Eli Lilly common stock at $1,183.16 per share on August 17, 2026, and now holds 55,745 shares.
2026-08-184Insider transaction report (Form 4)
Executive Vice President Patrik Jonsson sold 6,500 common shares of Eli Lilly at $1,175.10 each on August 17, 2026, reducing his holdings to 54,147 shares.
2026-08-184Insider transaction report (Form 4)
Director Juan R. Luciano received a grant of 13 Eli Lilly common shares at $1,183.16 each on 2026-08-17, increasing his holdings to 16,918 shares.
2026-08-184Insider transaction report (Form 4)
Director J Erik Fyrwald received an award of 8 common shares of Eli Lilly at $1,183.16 per share on 2026-08-17, now holding 75,418 shares.
2026-08-114Insider transaction report (Form 4)
On 2026-08-10, Eli Lilly officer Donald Zakrowski sold 2,000 common shares at $1,185.01 each, retaining 1,526 shares.
2026-08-104Insider transaction report (Form 4)
Hakim Anat disposed of 5,000 common shares in an open-market sale on 2026-08-07, at $1190 per share, leaving 11,875 shares owned.
2026-08-034Insider transaction report (Form 4)
Melissa Seymour (EVP, Global Quality) converted 981 RSUs into 981 common shares, then had 439 shares withheld for taxes at $1148.84 each.
2026-07-214Insider transaction report (Form 4)
Director Gabrielle Sulzberger received a grant of 4 shares of Eli Lilly common stock (A-Award, priced at $1,146.90) on 2026-07-20, bringing her total holdings to 3,000 shares.
2026-07-214Insider transaction report (Form 4)
Director J. Erik Fyrwald was awarded 9 shares of common stock on 2026-07-20 at $1,146.90, bringing his total holdings to 75,410 shares.
2026-07-214Insider transaction report (Form 4)
Director Ralph Alvarez received a grant of 11 shares of Eli Lilly common stock, bringing his total holdings to 55,734 shares.
2026-07-214Insider transaction report (Form 4)
Director Juan R. Luciano received a grant of 14 shares of Eli Lilly common stock (A-Award) on 2026-07-20, valued at $1,146.90 per share, bringing his total holdings to 16,905 shares.
2026-06-164Insider transaction report (Form 4)
Director J. Erik Fyrwald received an award of 9 common shares at $1129.35 each on 2026-06-15, bringing his total holdings to 75,401 shares.
2026-06-164Insider transaction report (Form 4)
Director Ralph Alvarez was awarded 11 shares of Eli Lilly common stock at $1,129.35 per share, bringing his total holdings to 55,723 shares.
2026-06-164Insider transaction report (Form 4)
Director Juan R Luciano received a grant of 14 shares of Eli Lilly common stock (valued at $1,129.35 each), bringing his total holdings to 16,891 shares.
2026-06-164Insider transaction report (Form 4)
Director Gabrielle Sulzberger was awarded 4 shares of Eli Lilly common stock at $1129.35 per share, bringing her total ownership to 2,995 shares.
2026-06-114Insider transaction report (Form 4)
Ilya Yuffa, EVP & President of LLY USA & Global Capabilities, sold 2,500 shares of Eli Lilly common stock on 2026-06-10 at $1,150.77 per share, leaving 29,804 shares owned afterward.
2026-05-194Insider transaction report (Form 4)
Director J. Erik Fyrwald received an award of 10 shares of common stock at $988.09 on 2026-05-18, bringing his total holdings to 75,280 shares.
2026-05-194Insider transaction report (Form 4)
Director Ralph Alvarez was awarded 13 shares of Eli Lilly common stock, bringing his total holdings to 55,627 shares.
2026-05-194Insider transaction report (Form 4)
Director Gabrielle Sulzberger was awarded 5 shares of Eli Lilly common stock, valued at $988.09 each, bringing her total holdings to 2,987 shares.
2026-05-194Insider transaction report (Form 4)
Director Juan R. Luciano was awarded 16 shares of Eli Lilly common stock, valued at $988.09 per share, bringing his total holding to 16,851 shares.
2026-05-074Insider transaction report (Form 4)
Lilly Endowment Inc, a former 10% shareholder of Eli Lilly, sold 15,828 shares of common stock on the open market at $995.23-$996.18 per share, leaving it with about 91.9M shares.
2026-04-214Insider transaction report (Form 4)
Director Ralph Alvarez was awarded 13 shares of Eli Lilly common stock (valued at $919.9 per share), bringing his total holdings to 55,615 shares.
2026-04-214Insider transaction report (Form 4)
Director Gabrielle Sulzberger received an award of 5 common shares at $919.90 on 2026-04-20, bringing her total ownership to 2,982 shares.
2026-04-214Insider transaction report (Form 4)
Director Juan R. Luciano was awarded 17 shares of Eli Lilly common stock, bringing his total holding to 16,835 shares.
2026-04-214Insider transaction report (Form 4)
Director J. Erik Fyrwald received a grant of 11 shares of Eli Lilly common stock at $919.90 on 2026-04-20, bringing his total holdings to 75,270 shares.
Transcripts
Earnings callsFY2026 Q32026-10-29
Earnings calls
AI summary
positiveLilly reported Q3 2026 revenue growth of 39% versus Q3 2025, driven by Mounjaro, Zepbound, and strong momentum across therapeutic areas; non-GAAP EPS were $7.48 including $4.57 of acquired IPR&D charges, compared with $7.20 in Q3 2025 including $0.71 of such charges. Gross margin rose 80 basis points to 84.4%, MS&A increased 14%, R&D increased 23%, and the non-GAAP performance margin was 54.2%, up 5.9 percentage points. U.S. revenue grew 34% on volume with price down 7% (10% excluding a favorable rebate/discount estimate adjustment); Europe grew 29% in constant currency including a $410 million one-time milestone, Japan 26%, China 62%, and rest of world 87%. Mounjaro and Zepbound combined for more than $16 billion of revenue. Management raised full-year revenue guidance to $91–92 billion and EPS to $35–36, and noted 2026 revenue benefited from approximately $2 billion of one-time items not expected to recur. Pipeline updates included retatrutide TRANSCEND T2D 2 head-to-head data versus semaglutide and multiple regulatory approvals. Lilly also acquired AtaiBeckley and Merida Biosciences and broke ground on manufacturing facilities in Houston and Richmond.
Key takeaways
- Q3 revenue grew 39% versus Q3 2025; Mounjaro and Zepbound combined for more than $16 billion of revenue and contributed $6 billion of growth.
- Full-year 2026 revenue guidance raised to $91–92 billion and non-GAAP EPS to $35–36, an increase of $4.07 per share at the midpoint before the Q3 acquired IPR&D charge update.
- Medicare GLP-1 bridge program: more than half a million people have filled a prescription for a Lilly medicine since the July 1 launch; about 7 in 10 new bridge patients start on a Lilly obesity medicine and roughly 80% are naive to therapy.
- Foundayo launched in four countries outside the U.S., is under review in more than 40 additional markets, and global rollout in all major markets is expected in 2027; U.S. type 2 diabetes regulatory action is expected in Q4.
- Lilly acquired AtaiBeckley and Merida Biosciences, broke ground on a $6.5 billion Houston facility and a $5 billion Richmond facility, distributed $1.5 billion of dividends, and executed $400 million of share repurchases.
Financial highlights
- Q3 revenue grew 39% versus Q3 2025; gross margin was 84.4%, up 80 basis points, and non-GAAP performance margin was 54.2%, up 5.9 percentage points.
- Non-GAAP EPS were $7.48 including $4.57 of acquired IPR&D charges, versus $7.20 in Q3 2025 including $0.71 of such charges.
- U.S. revenue grew 34% with price down 7% (down 10% excluding a favorable rebate and discount estimate adjustment); Europe grew 29% in constant currency including a $410 million one-time milestone.
- Japan revenue grew 26% in constant currency, China 62%, and rest of world 87% in constant currency; Q3 revenue included approximately $900 million from milestones and rebate/discount estimate changes.
Guidance
- FY2026 revenue expected between $91 and $92 billion.
- FY2026 non-GAAP performance margin expected at 52.5%; non-GAAP EPS expected at $35 to $36.
- 2027 guidance to be provided on the Q4 call in January; 2026 revenue included approximately $2 billion of one-time items not expected to recur.
- For 2027, net realized price is expected to be a headwind more than offset by volume growth, with full-year impact of the Medicare bridge program and the Foundayo type 2 diabetes launch.
Q&A themes
- Whether raised guidance reflects a fundamentally larger incretin opportunity versus pulled-forward demand, and what drove the roughly $10 billion increase versus initial guidance.
- Tirzepatide persistency and expectations for adherence with oral Foundayo versus injectables.
- Medicare bridge program mix (75% injectable), naive versus existing patients, and prospects for extension or permanent coverage.
- 2027 U.S. employer GLP-1 coverage trends, segment mix shifts toward Medicare and Medicaid, and international pricing discipline.
Risks
- Pricing is expected to remain a headwind: U.S. price fell 7% in Q3 (10% excluding a favorable estimate adjustment), and 2027 net realized price is expected to decline, partly offset by volume.
- 2026 results included approximately $2 billion of one-time items (milestones and rebate/discount estimate changes) that management does not expect to recur.
- Higher discontinuation due to adverse events occurred in the highest-dose Olora-TZP arm; Lilly plans slower, optimized dose escalation in Phase 3.
FY2026 Q22026-08-05
Earnings calls
AI summary
positiveEli Lilly delivered strong Q2 2026 results with revenue growth of 48% compared to Q2 2025, driven primarily by robust performance from Mounjaro and Zepbound, which combined for $14.9 billion in revenue. Key Products revenue increased by $6.8 billion, with Oncology, Immunology, and Neuroscience medicines growing 121% year-over-year. The company raised its full-year 2026 revenue guidance to $85-87 billion from the previous range. Gross margin expanded to 86.3%, while non-GAAP earnings per share reached $8.38. The company achieved multiple regulatory approvals and positive Phase 3 trial results across its pipeline, including approval for Ebglyss in atopic dermatitis maintenance dosing, EU approval for Jaypirca in CLL, and positive results from three retatrutide Phase 3 trials. Foundayo oral GLP-1 launch progressed in the U.S. with expansion of physician access and consumer marketing, and received approvals in Saudi Arabia and Mexico for obesity, with early uptake in the UAE being encouraging. The Medicare GLP-1 Bridge program launched July 1, expanding obesity medicine coverage to 20 million additional eligible Americans. The company announced acquisitions of AtaiBeckley for psychiatr
Key takeaways
- Revenue grew 48% in Q2 driven by Mounjaro and Zepbound combined sales of $14.9 billion; Oncology, Immunology, and Neuroscience grew 121% year-over-year
- Foundayo U.S. launch showed inflection point with week-over-week growth accelerating, increasing prescriber base from 8,000 to 36,000 and securing access across all major PBMs; international approvals received in UAE, Saudi Arabia, and Mexico
- Retatrutide Phase 3 program showed profound weight loss approaching bariatric surgery levels with demonstrated efficacy in obesity, type 2 diabetes with obesity, and severe obesity with cardiovascular disease; planned U.S. submission under BLA pathway in Q1 2027
- Company expanded into psychiatry through AtaiBeckley acquisition and into infectious disease vaccines through acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company to address significant unmet needs
- Medicare GLP-1 Bridge program launched July 1 providing $50/month coverage for eligible seniors, expanding U.S. obesity medicine access by 35% and driving inflection in both Zepbound and Foundayo prescriptions
Financial highlights
- Q2 2026 revenue growth of 48% compared to Q2 2025 with non-GAAP earnings per share of $8.38
- Mounjaro and Zepbound combined revenue of $14.9 billion in Q2 2026, contributing $6.3 billion of growth compared to Q2 2025
- Full-year 2026 revenue guidance raised to $85-87 billion from previous guidance; non-GAAP performance margin expected to be 49-50.5%; non-GAAP earnings per share guidance of $35.50-36.50
- Gross margin as percentage of revenue was 86.3% in Q2 2026, up 1.3 percentage points versus Q2 2025, driven by favorable product mix and improved cost of production
Guidance
- Planned global rollout of Foundayo in major markets in 2027 with more than 40 markets currently under regulatory review; expected readout of Phase 3 trial in obstructive sleep apnea later in 2026
- Retatrutide planned U.S. submission under BLA pathway in Q1 2027 with potential for indications in obesity, obstructive sleep apnea, and knee osteoarthritis pain
- Orforglipron U.S. submission completed for type 2 diabetes supported by ACHIEVE Phase 3 program; expectations for regulatory decisions and additional approvals throughout 2026
- Multiple anticipated clinical trial readouts through 2026 including additional retatrutide Phase 3 programs, EMBER-4 for Inluyro in adjuvant breast cancer, and lebrikizumab dosing frequency study results expected in 2027
Q&A themes
- Foundayo U.S. launch trajectory and inflection drivers: Company emphasized week-to-week prescription growth, recent doubling of volume in late July, new starts approaching 1 in 4, and progress with consumer awareness campaigns and prescriber education; executives noted Medicare Bridge program and expanded PBM access as key contributors to acceleration
- Retatrutide regulatory pathway and BLA classification: Company confirmed pursuing BLA pathway based on amino acid count rule and protein analogy; noted ongoing communication with FDA and expected submission timing in Q1 2027; emphasized unprecedented efficacy data and significant competitive lead with triple-acting medicine
- Medicare obesity coverage expansion: Initial observations showed approximately 80% preference for injectables with 60-70% of beneficiaries being new to obesity treatment; company noted inflection point in recent weeks for both Zepbound and Foundayo and continued focus on consumer and stakeholder education
- Competitive dynamics ex-U.S. for Foundayo: Company noted strong combined incretin share maintained despite second oral entrant in UAE market; emphasized early data should be interpreted cautiously with inventory build considerations; highlighted different regulatory requirements for international markets and broader 2027 launch timeline
Risks
- Foundayo U.S. launch slower than initially anticipated, requiring sustained investment in physician education, consumer awareness, and commercial access to drive inflection; company stated inflection point occurred in late July but sustained growth depends on continued execution across multiple fronts
- Retatrutide BLA regulatory classification remains subject to ongoing FDA negotiations and litigation; uncertain outcome could impact submission timeline or require alternative regulatory pathway, though company stated it will provide updates as progress is made
- International competitive pressure from Novo Nordisk oral GLP-1 with reported 50% market share achievement within 3 weeks of UAE launch; future pricing pressure and market share dynamics in non-U.S. markets could impact Foundayo penetration despite early demand signals
FY2026 Q12026-04-30
Earnings calls
AI summary
positiveLilly reported strong Q1 2026 results with revenue growth of 56% to $12.8 billion combined Mounjaro and Zepbound sales, raised full-year 2026 guidance to $82-85 billion, and achieved FDA approval for Koundeo (orforglipron), an oral GLP-1 for weight management. The company announced four acquisitions, reported positive Phase III data from five trials including Koundeo's cardiovascular outcomes study, and initiated six new Phase III programs. Gross margins remained strong at 82.6% despite a 7% U.S. price decline from negotiated outcomes.
Key takeaways
- Q1 revenue grew 56% YoY; key products (Elis, J. Perka, Kasanla, Monjaro, Umba) grew >$7 billion; immunology, oncology and neuroscience combined grew 160%
- Koundeo approved by FDA and launched; 20,000 patients treated to date with 80% of new prescriptions from new-to-class patients; commercial access confirmed at 2 of 3 largest PBMs by mid-May; Medicare bridge program begins July 1, 2026
- Raised 2026 revenue guidance midpoint to $83.5 billion (28% growth); non-GAAP EPS guidance raised to $35.50-$37.00; non-GAAP performance margin 50% in Q1, up 7 percentage points YoY
- Positive Phase III data: Koundeo showed 16% lower MACE risk and 57% lower all-cause mortality vs insulin glargine in ACHIEVE I; ratatrutide showed 1.7-2.0 percentage point A1c reduction and 11.1-16.6 kg weight loss in TRANSCEND T2D-1
- Acquired Orna, Syntessa, Colonia, and Ajax Therapeutics; 42 active Phase III programs ongoing with 6 newly initiated in obesity, osteoarthritis, sleep apnea, depression and other indications
Financial highlights
- Q1 2026 revenue: $12.8 billion combined Monjaro/Zepbound, total revenue grew 56% YoY
- Gross margin: 82.6% of revenue, down ~1 percentage point YoY, primarily from price pressure
- Non-GAAP EPS: $8.55 in Q1 2026 vs $3.34 in Q1 2025; raised full-year guidance to $35.50-$37.00
- 2026 revenue guidance raised to $82-85 billion (midpoint 28% growth); non-GAAP performance margin expected 47-48.5%; U.S. price expected to be headwind of low-to-mid teens for full year
Guidance
- 2026 full-year revenue guidance: $82-85 billion (up from prior $80-83 billion), representing 28% growth at midpoint
- Non-GAAP earnings per share: $35.50-$37.00 (raised from prior $33.50-$35.00); non-GAAP performance margin: 47-48.5%
- Koundeo Type 2 diabetes submission planned for late Q2 2026; regulatory action expected before end of 2026
- Plan to submit Koundeo in 40+ countries; expecting regulatory reviews ongoing in obesity and type 2 diabetes indications
Q&A themes
- Pricing dynamics: U.S. price declined 7% in Q1 including MFN agreement impact and direct-to-patient pricing; margin sensitivity limited due to fixed cost structure; company maintaining pricing discipline while seeing volume expansion
- International Mounjaro momentum: Launched in 55+ countries with strong market share gains (53% average OUS); generic semaglutide entry in India appears to stimulate overall market rather than reduce share; patient activation now key growth driver as market share matures
- Market segmentation: Portfolio expected to segment with GLP-1 single agonists, dual agonists (tirzepatide), oral GLP-1 (Koundeo), triple agonist (ratatrutide), and non-GLP-1 mechanisms (eloralintide); company positioned in leading position across multiple mechanisms
- Medicare coverage strategy: Bridge program extends through December 2027 with $50/month copay; Part D plans did not opt in for 2027; company expects government to push for normalization in commercial market and Part D participation in 2028; data on cost-effectiveness and population health outcomes expected to support coverage expansion
Risks
- U.S. price expected to remain headwind at low-to-mid teens for full year 2026; gross margin pressure from negotiated pricing despite volume growth
- Koundeo launch still in early stages with full DTC campaign delayed to Q3 2026; significant execution risk on consumer awareness and prescriber adoption of new oral GLP-1 molecule versus established injectables
- Medicare Part D coverage uncertainty: Part D plans declined to cover obesity medicines for 2027, requiring government bridge program extension; long-term normalization of commercial employer coverage still uncertain and incremental
FY2025 Q42026-02-04
Earnings calls
AI summary
positiveLilly delivered strong 2025 results with robust growth across obesity medicines Mounjaro and Zepbound, advanced a large clinical pipeline with 25+ positive Phase 3 trials, and expects 2026 revenue of $80-83 billion despite anticipated pricing headwinds in the low-to-mid teens. The company plans to launch oral GLP-1 Orforglipron in the US during 2026 and achieved market leadership in multiple categories including obesity, Alzheimer's, and diabetes therapies.
Key takeaways
- Full-year 2025 revenue reached $65.2 billion (45% growth), with Q4 revenue growing 43% year-over-year driven by obesity and cardiometabolic medicines
- 2026 revenue guidance of $80-83 billion (25% midpoint growth) reflects volume expansion offset by anticipated price declines in low-to-mid teens from Medicare access agreement, direct-to-patient pricing changes, and China reimbursement list inclusion
- Orforglipron (oral GLP-1) submitted to FDA for obesity with Q2 2026 approval expected; submitted in 40+ countries globally with most international launches anticipated in 2027
- Advanced 36 active Phase 3 programs with major 2025 achievements including positive data for retreutide (triple agonist showing 29% weight loss), Orforglipron maintenance data, and pirtobrutinib CLL trials demonstrating 76-80% risk reduction
- Zepbound achieved nearly 70% share of branded obesity new prescriptions in US; Mounjaro became share leader internationally; direct-to-consumer platform reached 1 million US patients with Zepbound vials representing ~50% of new starts
Financial highlights
- Full-year 2025 revenue: $65.2 billion (45% YoY growth); Q4 revenue grew 43% to approximately $17.9 billion based on quarterly progression
- Non-GAAP EPS grew 86% to $24.21 for full year 2025; Q4 EPS of $7.54 vs $5.32 in Q4 2024
- Non-GAAP performance margin of 47.2% in Q4 2025 (up 4.2 percentage points YoY); gross margin 83.2% stable with Q4 2024
- 2026 guidance: EPS of $33.50-$35.00; non-GAAP performance margin expected between 46-47.5%; R&D expenses expected to scale up with 36 active Phase 3 programs
Guidance
- 2026 revenue guidance: $80-83 billion (midpoint 25% growth vs 2025) driven by volume growth in key products partially offset by pricing headwinds in low-to-mid teens
- Price expected to decline low-to-mid teens in 2026 due to: US government obesity medicine access agreement ($50 copay), direct-to-patient Zepbound pricing updates, lower Medicaid prices for later lifecycle medicines, and China NRDL inclusion for Mounjaro
- Medicare obesity medicine access expected effective no later than July 1, 2026; expect Medicaid coverage reduction in 2026 but anticipate new state coverage additions in 2027
- Orforglipron US obesity launch expected during 2026; most international markets expected in 2027; six additional retreutide Phase 3 trials expected to read out in 2026
Q&A themes
- Orforglipron launch expectations focus on market expansion and patient satisfaction, with real-world efficacy and tolerability as key metrics; entry pricing expected similar to competitor oral semaglutide
- Medicare obesity access agreement expected to drive significant volume growth with $50 monthly copay as compelling value proposition; 10-20% of Lilly Direct patients estimated to transition to Medicare coverage
- Combination therapy opportunities being pursued across immunology, with Together PSA trial showing tirzepatide plus ixekizumab achieved primary endpoint with 64% relative improvement in psoriatic arthritis symptoms versus ixekizumab alone
- International Mounjaro momentum expected to continue with Q4 2025 as base for 2026 growth; China NRDL listing effective January 1, 2026 will moderately impact purchasing patterns; focus on market expansion and reimbursement gains in type 2 diabetes
Risks
- Significant anticipated pricing pressure in 2026 (low-to-mid teens decline) from Medicare access agreement, direct-to-patient pricing changes, China reimbursement listing, and Medicaid reductions could partially offset volume growth
- Competitive oral GLP-1 launch (semaglutide) is expanding market but cannibalization risk exists; company expects market expansion but cannot fully quantify out-of-pocket subscription dynamics relative to injectable therapies
- Late-lifecycle product declines expected in 2026 including Trulicity, Talsa, and Verzenio which could offset growth from new launches; Verzenio market penetration has plateaued in early breast cancer indication
FY2025 Q32025-10-30
Earnings calls
AI summary
positiveQ3 2025 delivered strong financial performance with 54% revenue growth and $12 billion from key products, primarily driven by Zepbound and Mounjaro. The company raised full-year revenue guidance to $63-$63.5 billion and non-GAAP EPS guidance to $23-$23.70. Major pipeline achievements included FDA approval of imlunestrant (Inluriyo) for ER+ breast cancer, EU approval of Kisunla for early symptomatic Alzheimer's disease, and positive Phase III results for oral GLP-1 candidate orforglipron showing superiority versus semaglutide.
Key takeaways
- Gross margin improved 140 basis points to 83.6% driven by favorable product mix; non-GAAP performance margin expanded over 800 basis points to 48.3%
- Mounjaro achieved 60%+ prescription growth in U.S. with 4 percentage point market share gain in incretin analog market; gained share for 5 consecutive quarters
- Orforglipron demonstrated weight loss of 10.5% and 7.8% at 36mg and 24mg doses respectively in ATTAIN-2, aligning with injectable GLP-1 monotherapy efficacy; regulatory submissions beginning imminently with U.S. launch anticipated in 2026
- Zepbound prescriptions tripled year-over-year with 71% share of new U.S. branded anti-obesity prescriptions; vials now comprise 30% of total and over 45% of new prescriptions
Financial highlights
- Q3 2025 revenue grew 54% year-over-year; raised full-year guidance to $63.0-$63.5 billion from prior $61.0-$61.5 billion range
- Non-GAAP EPS of $7.02 in Q3 2025 (includes $0.71 acquired IPR&D charges) versus $1.18 in Q3 2024; raised full-year EPS guidance to $23.00-$23.70
- U.S. revenue increased 45% driven by volume growth in Zepbound and Mounjaro, offset by 15% net price decline; international revenue grew 81% in constant currency excluding $380 million one-time milestone payment
- Non-GAAP performance margin of 48.3% represents 800+ basis point improvement from prior year quarter; R&D expenses increased 27% and MS&A expenses increased 31%
Guidance
- Full-year 2025 revenue guidance increased to $63.0-$63.5 billion (raised by approximately $2 billion at midpoint)
- Non-GAAP performance margin guidance of 45-46% of revenue for full-year 2025
- Non-GAAP EPS guidance of $23.00-$23.70 for full-year 2025
- Orforglipron U.S. launch anticipated for obesity treatment in 2026; type 2 diabetes submission expected in first half of 2026 pending ACHIEVE-4 results
Q&A themes
- Orforglipron commercial strategy balancing broad payer coverage with direct-to-consumer platform expansion via LillyDirect to maximize patient accessibility
- GLP-1 pricing dynamics: company maintaining pricing discipline at $349-$499 range on LillyDirect; noted tirzepatide's superior clinical efficacy versus semaglutide supports value positioning in payer negotiations
- International Mounjaro expansion momentum with 75% out-of-pocket payments for obesity indication across 55 launched markets; stocking effects seen in Q2 with continued growth in Q3
- Presymptomatic Alzheimer's program (TRAILBLAZER-3 and remternetug TRAILRUNNER-ALZ 3) maintaining enthusiasm based on prior trial data showing largest treatment effects in earliest disease stages
Risks
- U.S. net pricing pressure continues with high single-digit price declines excluding base period effects; CVS formulary changes created market disruption though Zepbound impact was modest
- Competitive dynamics intensifying with other manufacturers pursuing similar targets in obesity and incretin space; GLP-1 pricing could face pressure if semaglutide IRA negotiated price is more favorable than expected
- ATTAIN-MAINTAIN trial results uncertain with high bar for orforglipron to maintain weight loss versus maximal tirzepatide doses; trial outcome could significantly impact commercial opportunity
FY2025 Q22025-08-07
Earnings calls
AI summary
positiveLilly reported Q2 2025 revenue growth of 38% driven by Zepbound, Mounjaro, and other key products, with gross margins expanding 3 percentage points to 85%. The company announced top-line results from ATTAIN-1 showing orforglipron achieved 12.4% body weight loss at the highest dose, consistent with injectable GLP-1 safety profiles, while also announcing positive SURPASS-CVOT data for tirzepatide demonstrating cardiovascular benefits. The company raised 2025 revenue guidance to $60-62 billion and EPS guidance to $21.75-$23.
Key takeaways
- Q2 revenue grew 38% with strong performance from Zepbound ($3.4B) and Mounjaro ($5.2B); Mounjaro became U.S. market leader in total incretin prescriptions
- Orforglipron Phase III ATTAIN-1 trial met primary endpoint with patients at highest dose losing 27 pounds (12.4% body weight) with safety profile consistent with injectable GLP-1s
- SURPASS-CVOT demonstrated tirzepatide showed 8% lower MACE-3 event rate versus dulaglutide and 16% lower all-cause mortality; indirect comparison showed 28% MACE-3 reduction versus placebo
- Company increased incretin manufacturing capacity to 1.6x H1 2024 levels and expects 1.8x increase H2 2025 versus H2 2024; raised 2025 revenue guidance to $60-62B and EPS to $21.75-$23
Financial highlights
- Q2 2025 revenue grew 38% versus Q2 2024 to record levels driven by key products
- Gross margin expanded to 85% in Q2, up 3 percentage points year-over-year, driven by improved cost of production and favorable product mix partially offset by lower realized prices
- Q2 non-GAAP EPS increased 61% to $6.31; performance margin reached 45.9%
- Zepbound sales of $3.4B in Q2; Mounjaro sales of $5.2B in Q2; cash vials represented approximately 20% of total U.S. Zepbound prescriptions and over 35% of new prescriptions
Guidance
- 2025 revenue guidance raised to $60-62 billion (prior guidance not specified in transcript)
- 2025 non-GAAP EPS guidance raised to $21.75-$23
- Non-GAAP performance margin expected to be 43-45.5% for full year 2025
- Expects to produce at least 1.8x incretin salable doses in H2 2025 versus H2 2024; plan to announce location of 2 new U.S. manufacturing facilities later in Q3
Q&A themes
- Orforglipron positioned for patients with less complex obesity and mass market reach; management expects similarly encouraging results in ATTAIN-2; expects submissions for obesity indications by year-end 2025
- Compounding and Canadian generic semaglutide discussed as ongoing headwinds; company emphasized patient safety concerns and reliance on regulators/law enforcement; pricing philosophy emphasizes value-based approach with single-digit net pricing erosion expected
- CVS formulary exclusion of Zepbound estimated to impact couple hundred thousand TRx; management noted impact still early but expects headwind to Q3 growth rate; July TRx data showed recovery toward May levels
- Employer coverage for anti-obesity medicines at 50-55% opt-in; new benefit designs emerging that may increase opt-ins; LillyDirect vial channel growing with over 1 million TRx in Q2 and 20% of total Zepbound prescriptions
Risks
- CVS pharmacy benefit manager exclusion of Zepbound from July 1 expected to be headwind to Q3 volume growth rate; continued compounding and potential Canadian generic semaglipride competition may pressure pricing
- Orforglipron efficacy profile compared to Novo's semaglutide oral appears modestly lower; cross-trial comparisons suggested potential need for higher dose exploration
- Drug pricing reform discussions ongoing with administration; potential for new legislation could impact pricing strategy and international market dynamics; potential tariff impacts remain dynamic but currently expected to be modest
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.- China approves Eli Lilly's weight loss pill orforglipron
- Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound
- Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
- Eli Lilly international business chief Jonsson to retire; Yuffa to head global markets unit
- Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech
- Experimental Lilly combination drug tops Zepbound in weight-loss trial
- A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study
- Lilly's experimental drug cuts weight by 21% in diabetes trial
- US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes
- China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
Company data
Company intelligence
Updated: Nov 13, 2026, 02:14 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- David A. Ricks
- Employees
- 50,000
- IPO date
- Jun 1, 1972
- Country
- US
- Exchange
- New York Stock Exchange
Altman Z-scorei9.57
Piotroski scorei7/9
Overall ratingiB
Owner earningsi$10.71B$11.99 per share
ESG risk ratingiB+Industry rank: 10/28
Rating factors
- Return on equityi
- 5/5
- Return on assetsi
- 5/5
- Debt to equityi
- 1/5
- Price to earningsi
- 1/5
- Price to booki
- 1/5
Company press releases
Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020PRNewsWireNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesityPRNewsWireLife doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waitingPRNewsWireLilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight lossPRNewsWireLilly and Hims & Hers expand access to FDA-approved Lilly medicinesPRNewsWireLilly and Hims & Hers expand access to FDA-approved Lilly medicinesBusiness Wire
Congressional disclosures
Senate
Alan ArmstrongSale (Full) · $1,001 - $15,000Disclosed: Jul 21, 2026Angus KingSale (Full) · $1,001 - $15,000Disclosed: Mar 24, 2026Angus Stanley KingSale · $1,001 - $15,000Disclosed: Mar 24, 2026Angus KingSale · $1,001 - $15,000Disclosed: Mar 24, 2026Angus KingPurchase · $1,001 - $15,000Disclosed: Jan 26, 2026
House
Gilbert CisnerosPurchase · $1,001 - $15,000Disclosed: Nov 10, 2026Ro KhannaPurchase · $1,001 - $15,000Disclosed: Oct 9, 2026Daniel Milton NewhouseSale (Partial) · $1,001 - $15,000Disclosed: Jul 20, 2026Daniel Milton NewhouseSale · $1,001 - $15,000Disclosed: Jul 20, 2026Dan NewhouseSale · $1,001 - $15,000Disclosed: Jul 20, 2026
Market cap history
$1.30T+19.0%Aug 2026 – Nov 2026
Latest: $1.30T · 2026-11-12High: $1.30T · 2026-11-12Low: $1.00T · 2026-09-08
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| 189400.KS | 1.09% | 10.9T |
| VTS.AX | 1.34% | 27.5M |
| VTI | 1.34% | 26.9M |
| VOO | 1.41% | 21M |
| VCPA.S | 0.36% | 16.9M |
| IVV | 1.77% | 10.7M |
| 1657.T | 1.35% | 10.7M |
| XAW.TO | 1.04% | 10.7M |
| XUU.TO | 1.57% | 10.7M |
| XWD.TO | 1.27% | 10.7M |
| SPY | 1.77% | 9.8M |
| VUG | 2.6% | 8.8M |
Analyst track record
How the analysts covering LLY have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 278 | 837 |
| Analysts | 31 | 43 |
| Buy / hold / sell | 259 / 16 / 3 | 771 / 62 / 4 |
| Upgrades / downgrades / initiations | 3 / 1 / 2 | 12 / 8 / 8 |
| Price targets hit / missed | 205 / 53 (79%) | 686 / 54 (93%) |
| Avg. return after a rating (TipRanks) | +7.7% | +37.5% |
| Best / worst call | +67.9% / -16.0% | +249.8% / -16.0% |
After buy calls on this stock: median 21-day move +1.8% vs S&P 500 -0.6% (n = 784)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Louise ChenScotiabank100% hit rate on this stock · 15 targets measuredBuytarget $1,605Oct 30, 2026
- Asad HaiderGoldman Sachs100% hit rate on this stock · 11 targets measuredBuytarget $1,573Oct 30, 2026
- Courtney BreenBernstein97% hit rate on this stock · 36 targets measuredBuytarget $1,450Oct 26, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 9, 2026 | Akash TewariJefferiesNov 9, 2026 | BuyMaintained | $1,700↗ | article ↗ |
| Nov 5, 2026 | Jason GerberryBank of America SecuritiesNov 5, 2026 | BuyReiterated | $1,557↗ | article ↗ |
| Nov 2, 2026 | David RisingerLeerink PartnersNov 2, 2026 | BuyMaintained | $1,508↗ | article ↗ |
| Nov 1, 2026 | Carter GouldCantor FitzgeraldNov 1, 2026 | BuyMaintained | $1,600↗ | article ↗ |
| Oct 30, 2026 | Ilya ZubkovFreedom Capital MarketsOct 30, 2026 | BuyMaintained | $1,600↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 13, 2026 · 278 ratings
Frequently asked questions
Where can I trade LLY perpetual futures?
Eli Lilly and Company (LLY) perpetual futures trade on 20 crypto venues, including Deepcoin, Binance, Ourbit. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade LLY around the clock?
Yes. Unlike the underlying stock, LLY perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on LLY perpetuals?
Right now the LLY perp funding rate is +2.7% annualized (venue median), ranging from 0.0% to +5.5% across 20 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the LLY perp price compare to the Eli Lilly and Company stock?
The venue-median LLY perp mark is $1.4K versus a reference stock price of $1.4K, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a LLY perpetual future?
A LLY perpetual is a derivative that tracks the price of Eli Lilly and Company with no expiry date. It lets you take long or short exposure to Eli Lilly and Company on crypto venues, around the clock.
What is LLYUSDT perpetual?
LLYUSDT is the symbol most crypto exchanges use for the Eli Lilly and Company perpetual settled in USDT (Tether). It tracks the LLY share price through an index, trades 24/7 with leverage and never expires.
Embed this asset
<a href="https://perpequities.com/stocks/lly-perp"><img src="https://perpequities.com/badge/lly-perp.svg" width="240" height="64" alt="LLY perpetuals · perpequities.com" loading="lazy"></a>